Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Quantum BioPharma will present at the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026, with co-founder and Executive Co-chairman Anthony Durkacz covering recent milestones and the company's growth strategy. The summit brings together growth issuers with institutional investors, family offices, and capital-markets professionals for a day of presentations, panels, and curated 1-on-1 meetings. The release contains no new financial, clinical, or regulatory data; it restates the company's positioning, including lead compound Lucid-MS for multiple sclerosis and a 19.48% stake in Unbuzzd alongside 7% royalties on sales until payments reach $250 million.
Key figures
- Royalty cap
- $250 million
- Unbuzzd royalty rate
- 7% of sales until payments total $250 million, then 3% in perpetuity
- Unbuzzd ownership pct
- 19.48%
- Unbuzzd ownership asof
- June 30, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.